Literature DB >> 18761606

A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection.

J Zhou1, D K Smith, L Lu, V K M Poon, F Ng, D-Q Chen, J-D Huang, K-Y Yuen, K-Y Cao, B-J Zheng.   

Abstract

The type I interferon (IFN-alpha/beta) receptor 1 (IFNAR1) mediates the potent antiviral and immuno-regulatory effects of IFN-alpha/beta that are believed to be pivotal to eradicate hepatitis B virus (HBV) infection. IFNAR1 promoter polymorphisms (at -568/-77) have been shown to be associated with susceptibility to chronic HBV infection; however, whether these markers are genetic determinants of HBV infection remains unknown. The functional significance of promoter -568/-77 polymorphisms was assessed by mutagenesis and luciferase assays. Sequencing and restriction fragment length polymorphisms in 328 chronic HBV patients, 130 spontaneous resolvers and 148 healthy blood donors identified other polymorphism at IFNAR1 open reading frame. IFNAR1 expression levels in peripheral blood cells were detected by flow cytometry. We found that the -568/-77 promoter variants were unlikely to affect transcription levels. A C/G single nucleotide polymorphism, in strong linkage disequilibrium with the promoter polymorphisms, was found in the coding sequence of IFNAR1 (nt19158). This resulted in a nonsynonymous substitution in the extracellular region of IFNAR1 protein and correlated with susceptibility to chronic HBV infection. Bioinformatic analysis suggested decreased stability of the IFNAR1 protein. Chronic HBV patients with the 19158C/C genotype (Leu141) exhibited higher IFNAR1 protein expression levels in peripheral blood monocytes than those with the 19158G/G genotype (Val141). In conclusion, IFNAR1 19158C/G polymorphism is primarily associated with susceptibility to chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761606     DOI: 10.1111/j.1365-2893.2008.01040.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

2.  Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice.

Authors:  Yi-Jiun Lin; Hui-Lin Wu; Ding-Shinn Chen; Pei-Jer Chen
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

3.  Innate antiviral immune responses to hepatitis B virus.

Authors:  Malika Ait-Goughoulte; Julie Lucifora; Fabien Zoulim; David Durantel
Journal:  Viruses       Date:  2010-07-05       Impact factor: 5.818

4.  A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans.

Authors:  Guoliang Zhang; Nicole A deWeerd; Sebastian A Stifter; Lei Liu; Boping Zhou; Wenfei Wang; Yiping Zhou; Binwu Ying; Xuejiao Hu; Antony Y Matthews; Magda Ellis; James A Triccas; Paul J Hertzog; Warwick J Britton; Xinchun Chen; Carl G Feng
Journal:  Nat Commun       Date:  2018-01-08       Impact factor: 14.919

5.  Interferon-α inhibits cell migration and invasion and induces the expression of antiviral proteins in Huh-7 cells transfected with hepatitis B virus X gene-expressing lentivirus.

Authors:  Qian Yang; Xiao-Peng Li; Yuan-Bin Zhong; Tian-Xin Xiang; Lun-Li Zhang
Journal:  Exp Ther Med       Date:  2017-10-11       Impact factor: 2.447

6.  Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response.

Authors:  Krist Helen Antunes; José Luís Fachi; Rosemeire de Paula; Emanuelle Fraga da Silva; Laís Passariello Pral; Adara Áurea Dos Santos; Greicy Brisa Malaquias Dias; José Eduardo Vargas; Renato Puga; Fabiana Quoos Mayer; Fábio Maito; Carlos R Zárate-Bladés; Nadim J Ajami; Marcella Ramos Sant'Ana; Thamiris Candreva; Hosana Gomes Rodrigues; Marcio Schmiele; Maria Teresa Pedrosa Silva Clerici; José Luiz Proença-Modena; Angélica Thomas Vieira; Charles R Mackay; Daniel Mansur; Mauricio T Caballero; Jacqui Marzec; Jianying Li; Xuting Wang; Douglas Bell; Fernando P Polack; Steven R Kleeberger; Renato T Stein; Marco Aurélio Ramirez Vinolo; Ana Paula Duarte de Souza
Journal:  Nat Commun       Date:  2019-07-22       Impact factor: 14.919

7.  Congenital Zika Syndrome Is Associated With Interferon Alfa Receptor 1.

Authors:  Tamiris Azamor; Daniela Prado Cunha; Andréa Marques Vieira da Silva; Ohanna Cavalcanti de Lima Bezerra; Marcelo Ribeiro-Alves; Thyago Leal Calvo; Fernanda de Souza Gomes Kehdy; Fernanda Saloum de Neves Manta; Thiago Gomes de Toledo Pinto; Laís Pereira Ferreira; Elyzabeth Avvad Portari; Letícia da Cunha Guida; Leonardo Gomes; Maria Elisabeth Lopes Moreira; Elizeu Fagundes de Carvalho; Cynthia Chester Cardoso; Marcelo Muller; Ana Paula Dinis Ano Bom; Patrícia Cristina da Costa Neves; Zilton Vasconcelos; Milton Ozório Moraes
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

8.  A functional polymorphism in IFNAR1 gene is associated with susceptibility and severity of HFMD with EV71 infection.

Authors:  Rongrong Zou; Guoliang Zhang; Shaoyuan Li; Wenfei Wang; Jing Yuan; Jianming Li; Yanrong Wang; Yimin Lin; Yong Deng; Boping Zhou; George Fu Gao; Yingxia Liu
Journal:  Sci Rep       Date:  2015-12-18       Impact factor: 4.379

9.  Impact of Interferon-α Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Timokratis Karamitros; George Papatheodoridis; Dimitrios Paraskevis; Angelos Hatzakis; Jean L Mbisa; Urania Georgopoulou; Paul Klenerman; Gkikas Magiorkinis
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.